___

• A. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002; 137:617.
• Sathasivam S, Lecky B Statin induced myo- pathy.BMJ. 2008 Nov 6;337:2286
• Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012 Jun;23(4):317-24
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; Ameri- can College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Sta- tins.Stroke. 2002 Sep;33(9):2337-41
• Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14
• Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P Meta- analysis of drug-induced adverse events associated with intensive-dose statin the- rapy Clin Ther. 2007 Feb;29(2):253-60
• Antons KA, Williams CD, Baker SK, Phillips PS.Clinical perspectives of statin-induced rhabdomyolysis Am J Med. 2006 May;119(5):400-9
• Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospi- talized rhabdomyolysis with statin and fib- rate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9.
• Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstİl K, Bryniarski L, Császár A, Vanderbist F. Safety of a fixed- dose te/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clin Drug Investig. 2012 Apr 1;32(4):281-91
• Davidson MH, Armani A, McKenney JM, Ja- cobson TA Safety considerations with fibra- te therapy Am J Cardiol. 2007 Mar 19;99(6A):3C-18C
• Baer AN, Wortmann RL Myotoxicity associ- ated with lipid-lowering drugs Curr Opin Rheumatol. 2007 Jan;19(1):67-73
• Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur Dec;65(12):1169-74 2009